Cancer Cell Biology Research Program

癌细胞生物学研究计划

基本信息

批准号：
10534176
负责人：
JAMES E BEAR
金额：
$ 4.51万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-06-01 至 2025-11-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10534176
关键词：
Actins Address Apoptosis Area Basic Science Biochemistry Biology Biophysics Blood Vessels Cancer Center Support Grant Cancer Intervention Catchment Area Cell Cycle Cell Cycle Regulation Cell physiology Cells Cellular biology Chromatin Clinical Clinical Sciences Clinical Trials Collaborations Communities Community Outreach Complex Core Facility Cullin Proteins Cytoskeleton DNA DNA Modification Process DNA Repair DNA biosynthesis Development Dioxygenases Direct Costs Disparity Doctor of Philosophy Education Educational process of instructing Electronic cigarette Entrepreneurship Environment Enzymes Epigenetic Process Equipment Event Extramural Activities Faculty Faculty Recruitment Family Fostering Funding Genomics Goals Grant Growth Factor Institution Intervention Investments Joints Knowledge Lung Malignant Neoplasms Malignant neoplasm of lung Malignant neoplasm of pancreas Mentors Mentorship Metabolism Modeling Molecular Multiple Myeloma Neoplasm Metastasis North Carolina Output Pancreas Pathway interactions Phase Phenotype Pilot Projects Population Population Sciences Productivity Program Development Prostate Publishing RNA Recording of previous events Regulation Research Research Activity Research Personnel Resistance Resource Sharing Role Scientist Seminal Signal Pathway Signal Transduction Structure Talents Technology Testing Therapeutic Therapeutic Intervention Tissues Training Transcriptional Regulation Translating Translations Tumor Cell Invasion Tumor Suppression Ubiquitin angiogenesis anticancer research cancer cell cancer therapy career cell motility commercialization community engagement drug discovery effective therapy high school histone modification improved insight interest junior high school malignant breast neoplasm meetings melanoma member migration neoplastic cell new therapeutic target novel diagnostics novel therapeutics peer pre-clinical preclinical trial professor programs receptor research and development response small molecule inhibitor symposium targeted cancer therapy therapeutic target tumor tumor initiation tumor progression tumorigenesis ubiquitin-protein ligase

项目摘要

ABSTRACT: CANCER CELL BIOLOGY PROGRAM The overarching goals of the Cancer Cell Biology (CCB) Program are: (i) to understand, at the molecular and cellular levels, mechanisms underlying tumor initiation, progression, metastasis and resistance to therapeutic treatment, and (ii) to identify and validate new targets for cancer therapy. Insight derived from these studies, when integrated with research and development from other programs, will provide targets and guidance for the development of strategies for therapeutic intervention of cancer. Toward these two goals, the Program faculty investigate various aspects of cancer cell biology, including growth factors and receptors; angiogenesis and vascular biology; apoptosis; cell cycle regulation; chromatin biochemistry and transcriptional regulation; cell microstructure and function; DNA replication and repair; metabolism; regulatory RNA; and signal transduction. Led by two co-leaders with complementary expertise, Yue Xiong and James Bear, the program organizes these different areas into four major research aims: (1) Cell Cycle, (2) Cell Signaling, (3) Cell Movement and Organization, and (4) Chromatin Biology. The major emphasis of the Program is to foster integrated research that spans these inter-related themes, enhancing the research and translational capabilities of program investigators through the establishment, expansion and utilization of appropriate core facilities, and promoting interactions with investigators from other LCCC basic, clinical and population sciences programs. CCB has made concerted and focused efforts to improve translational output, by fostering inter-programmatic collaboration directed towards translation of basic science discoveries, engaging in entrepreneurship and brining small molecule inhibitors to pre-clinical and clinical trials. The research of CCB addresses fundamental biology that applies to all cancers but has a particular impact on cancers relevant to our catchment area such as multiple myeloma, lung cancer and melanoma. In addition, members of CCB have been active in community outreach and engagement activities such as advising state legislators on e-cigarette regulation. Finally, the members of CCB are fully committed to education, training and mentoring at levels ranging from middle schoolers through junior faculty at our own institution. The Cancer Cell Biology Program consists of 43 members who are associated with 12 basic science and 3 clinical departments at UNC-Chapel Hill and affiliated institutions. During the last funding period, program members published 740 cancer-related articles. Of these, 23% were inter-programmatic and 10% were intra- programmatic (31% collaborative). In 2019, our program members held grants totaling $18.2M (direct cost) in cancer-relevant extramural funding, including $3.5M (direct costs) from the NCI and $13.6M other peer.

摘要：癌细胞生物学计划癌细胞生物学（CCB）计划的总体目标是：（i）在分子和细胞水平，肿瘤起始的基础机制，进展，转移和对治疗性的耐药性治疗和（ii）确定和验证癌症治疗的新靶标。从这些研究中获得的洞察力，与其他计划的研究和开发集成时，将为目标和指导提供制定癌症治疗干预策略。针对这两个目标，该计划教师研究癌细胞生物学的各个方面，包括生长因子和受体；血管生成和血管生物学；凋亡；细胞周期调节；染色质生物化学和转录调节；细胞微结构和功能； DNA复制和修复；代谢;调节RNA；和信号转导。该计划由两个具有互补专业知识的联合领导者Yue Xiong和James Bear领导，该计划组织这些不同的区域分为四个主要研究目的：（1）细胞周期，（2）细胞信号传导，（3）细胞运动和组织和（4）染色质生物学。该计划的主要重点是培养综合研究跨越这些相互关联的主题，增强了程序的研究和翻译能力通过建立，扩展和利用适当的核心设施的调查人员，并促进与其他LCCC基本，临床和人口科学计划的研究人员的互动。 CCB有通过促进程序间置换，做出了共同和集中的努力来改善翻译产出致力于翻译基础科学发现的合作，从事企业家精神和将小分子抑制剂带到临床前和临床试验。 CCB的研究解决了基本适用于所有癌症的生物学，但对与我们的集水区相关的癌症有特殊的影响作为多发性骨髓瘤，肺癌和黑色素瘤。此外，CCB的成员已经活跃社区宣传和参与活动，例如向州议员就电子烟法规提供建议。最后，CCB的成员完全致力于教育，培训和指导，从中学生通过我们自己机构的初级教师。癌细胞生物学计划由43位与12个基础科学相关的成员和3个成员 UNC-Chapel Hill和附属机构的临床部门。在上一个资金期间，计划成员发表了740篇与癌症相关的文章。其中，有23％是程序间的，10％为程序化（31％协作）。 2019年，我们的计划成员持有总计1820万美元的赠款（直接费用）与癌症相关的校外资金，包括NCI的350万美元（直接费用）和其他同行1360万美元。